Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Apraglutide by Ironwood Pharmaceuticals for Short Bowel Syndrome: Likelihood of Approval
Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Ironwood Pharmaceuticals's Apraglutide?
Apraglutide is a synthetic peptide commercialized by Ironwood Pharmaceuticals, with a leading Phase III program in Short Bowel Syndrome. According...
Apraglutide by Ironwood Pharmaceuticals for Short Bowel Syndrome: Likelihood of Approval
Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Ironwood Pharmaceuticals's Apraglutide?
Apraglutide is a synthetic peptide commercialized by Ironwood Pharmaceuticals, with a leading Phase III program in Short Bowel Syndrome. According...